查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1700069

2032 年生物性骨材市場預測：按產品類型、分銷管道、應用、最終用戶和地區進行的全球分析

Orthobiologics Market Forecasts to 2032 - Global Analysis By Product Type (Bone Grafts, Growth Factors, Platelet-Rich Plasma (PRP), Stem Cells, Cell-Based Therapies and Other Product Types), Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球生物性骨材市場預計在 2025 年達到 72 億美元，到 2032 年將達到 112 億美元，預測期內的複合年成長率為 6.5%。

生物性骨材是利用生物材料和物質來促進肌肉骨骼疾病的癒合和修復。這些治療方法包括幹細胞、富血小板血漿 (PRP)、生長因子和細胞外基質蛋白，這些可能來自身體或合成產生。在整形外科中，生物製藥通常用於透過促進組織再生、減少發炎和加速癒合過程來治療損傷和退化性疾病。對於關節、韌帶、肌腱和骨骼受傷的患者來說，這種方法提供了一種比手術更自然的替代方法，有可能改善治療效果並縮短恢復時間。

根據ISAPS全球調查，2022年整形外科醫師實施的手術數量增加了11.2%。全球共實施了約1880萬例非手術手術和1490萬例手術手術，延續了過去四年41.3%的成長趨勢。

微創手術需求不斷成長

市場對微創手術的需求不斷成長，因為與傳統手術相比，微創手術恢復時間更短、併發症風險更低、術後疼痛更少。患者越來越青睞這些手術，因為它們可以治療肌肉骨骼損傷，同時最大限度地減少對周圍組織的損傷。隨著技術的進步和認知的提高，PRP 和幹細胞療法等微創骨科生物療法的應用預計將繼續成長並改變整形外科的格局。

缺乏標準化

市場缺乏標準化帶來了重大挑戰，包括治療結果不一致和安全問題。如果沒有明確的指導方針，幹細胞注射和富血小板血漿 (PRP) 等治療方法的品質和效果可能會有很大差異，並為患者帶來不可預測的結果。這種不一致會破壞患者的信任並阻礙其廣泛採用。此外，缺乏標準化協議使監管監督變得複雜，並增加了未經證實或不安全的治療方法進入市場並傷害患者的可能性。

再生醫學意識不斷增強

隨著患者和醫療保健提供者認知到再生醫學在治療和組織修復方面的潛力，人們對再生醫學的認知不斷提高，這對市場產生了重大影響。再生療法，例如幹細胞療法和富血小板血漿（PRP），為治療肌肉骨骼損傷和退化性疾病提供了一個有希望的傳統手術替代方案。隨著教育和研究的進步，越來越多的人正在尋求這些創新治療方法，以便更快地康復並取得更好的結果。這種日益增強的認知正在推動再生醫學在骨科生物學應用中日益成長的需求和擴展。

治療費用高昂

市面上治療費用高昂，限制了許多患者獲得這些先進療法的機會，尤其是那些沒有足夠保險的患者。幹細胞療法和富血小板血漿 (PRP) 注射等昂貴治療的經濟負擔可能導致一些患者放棄可能有益的治療。這不僅造成了醫療保健機會的不平等，而且還減緩了生物性骨材的廣泛應用。

COVID-19的影響：

COVID-19 疫情擾亂了供應鏈，推遲了選擇性手術，並限制了患者接受治療的機會，對市場產生了重大影響。許多整形外科診所和醫院暫停了非緊急護理，減少了對幹細胞療法和 PRP 注射等再生治療的需求。此外，經濟拮据和對感染風險的擔憂導致患者推遲或放棄治療。然而，疫情也可能加速人們對微創、非手術治療的興趣，進而推動未來的市場成長。

腰椎融合手術預計將成為預測期內最大的手術市場

腰椎融合部分包括骨移植和幹細胞以促進脊椎骨的癒合和融合，預計在預測期內將佔據最大的市場佔有率。透過整合骨科生物療法，腰椎融合旨在促進癒合、減少併發症並改善患者預後。隨著微創技術越來越普及，脊椎外科再生療法的需求預計會增加，為患者提供更好的復健選擇。

預計牙科診所部門在預測期內將實現最高的複合年成長率。

預計牙科診所部門將在預測期內見證最高的成長率。這些生物療法有助於促進組織再生、減少發炎並提高牙科手術的整體成功率。隨著人們對再生醫學認知的不斷提高，越來越多的牙科專業人士將生物性骨材納入他們的實踐中，為患者提供先進的微創治療選擇，以實現更快的康復和更好的長期效果，從而推動了牙科行業的需求。

佔比最大的地區：

在預測期內，由於醫療保健意識的提高，預計亞太地區將佔據最大的市場佔有率。日本、中國和印度等國家擴大採用幹細胞療法、富血小板血漿 (PRP) 和骨移植等治療方法。醫療保健基礎設施的成長和向微創治療的轉變正在推動對生物製藥的需求。法律規範的改善和醫療研究和技術投資的增加也為市場提供了支持。

複合年成長率最高的地區：

預計北美地區在預測期內將呈現最高的複合年成長率。再生醫學的技術進步，例如幹細胞療法、基因療法和富血小板血漿 (PRP) 療法，正在提高骨科生物療法的有效性。此外，隨著越來越多的患者和醫療保健專業人員了解骨生物學療法的益處，包括加速癒合和減少對傳統藥物和手術的依賴，對這些治療的需求正在增加。

免費客製化服務：

訂閱此報告的客戶可以享受以下免費自訂選項之一：

  • 公司簡介
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球生物性骨材市場（依產品類型）

  • 骨移植
    • 自體移植
    • 同種異體移植
    • 合成骨移植
  • 生長因子
    • 骨形成蛋白（BMP）
    • 血小板衍生生長因子（PDGF）
    • 血管內皮生長因子（VEGF）
    • 轉化生長因子BETA（TGF-B）
    • 胰島素樣生長因子（IGF）
  • 富血小板血漿（PRP）
  • 幹細胞
    • 間質幹細胞（MSCs）
    • 造血幹細胞
    • 誘導性多功能幹細胞（iPSC）
  • 細胞治療方法
    • 自體細胞療法
    • 同種異體細胞治療
  • 其他產品類型

6. 全球生物性骨材市場（依分銷管道）

  • 直銷
  • 間接銷售
  • 電商平台

7. 全球生物性骨材市場（按應用）

  • 頸椎融合手術
  • 腰椎融合手術
  • 胸椎融合術
  • 髖關節置換術
  • 肩關節重組手術
  • 人工植牙
  • 傷口癒合
  • 微骨折手術
  • 韌帶修復
  • 其他用途

8. 全球生物性骨材市場（依最終用戶分類）

  • 醫院
  • 門診手術中心
  • 整形外科診所
  • 牙醫診所
  • 復健中心
  • 研究組織
  • 其他最終用戶

9. 全球生物性骨材市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Bioventus LLC
  • Nuvasive, Inc.
  • Anika Therapeutics, Inc.
  • Alphatec Spine, Inc.
  • Medtronic plc
  • Stryker Corporation
  • Globus Medical, Inc.
  • Xtant Medical Holdings, Inc.
  • Sanofi SA
  • Orthofix Medical Inc.
  • Bone Therapeutics SA
  • RTI Surgical, Inc.
  • Kuros Biosciences Ltd.
  • Smith & Nephew plc
  • Integra LifeSciences Holdings Corporation
  • Seaspine Holdings Corporation
  • Arthrex, Inc.
Product Code: SMRC28972

According to Stratistics MRC, the Global Orthobiologics Market is accounted for $7.2 billion in 2025 and is expected to reach $11.2 billion by 2032 growing at a CAGR of 6.5% during the forecast period. Orthobiologics is the use of biological materials and substances to promote healing and repair in musculoskeletal conditions. These therapies include stem cells, platelet-rich plasma (PRP), growth factors, and extracellular matrix proteins, which are derived from the body or synthesized. Orthobiologics are often used in orthopedics to treat injuries or degenerative diseases by stimulating tissue regeneration, reducing inflammation, and accelerating healing processes. This approach offers a more natural alternative to surgery, with the potential for improved outcomes and reduced recovery times for patients with joint, ligament, tendon, or bone injuries.

According to the ISAPS Global Survey, the number of procedures performed by plastic surgeons increased by 11.2% in 2022. About 18.8 million non-surgical and 14.9 million surgical procedures were performed worldwide, continuing the trend of a 41.3% increase over the last four years.

Market Dynamics:

Driver:

Growing demand for minimally invasive procedures

The growing demand for minimally invasive procedures in the market is driven by their ability to offer faster recovery times, reduced risk of complications, and less post-operative pain compared to traditional surgeries. Patients increasingly prefer these procedures due to their effectiveness in treating musculoskeletal injuries with minimal disruption to surrounding tissues. As technologies improve and awareness rises, the adoption of minimally invasive Orthobiologic treatments like PRP and stem cell therapies is expected to continue growing, transforming the landscape of orthopedic care.

Restraint:

Lack of standardization

The lack of standardization in the market poses significant challenges, including inconsistent treatment outcomes and safety concerns. Without clear guidelines, the quality and efficacy of therapies like stem cell injections and platelet-rich plasma (PRP) can vary widely, leading to unpredictable results for patients. This inconsistency undermines patient trust and can hinder widespread adoption. Additionally, the absence of standardized protocols complicates regulatory oversight, increasing the risk of unproven or unsafe treatments entering the market and potentially harming patients.

Opportunity:

Rising awareness of regenerative medicine

Rising awareness of regenerative medicine is significantly influencing the market, as patients and healthcare providers recognize its potential for healing and tissue repair. Regenerative treatments, such as stem cell therapy and platelet-rich plasma (PRP), offer promising alternatives to traditional surgeries, addressing musculoskeletal injuries and degenerative conditions. As education and research advance, more people are seeking out these innovative treatments for faster recovery and improved outcomes. This growing awareness is driving the increasing demand and expansion of regenerative medicine in orthobiologic applications.

Threat:

High cost of treatments

The high cost of treatments in the market limits access to these advanced therapies for many patients, particularly those without adequate insurance coverage. Expensive procedures like stem cell therapy or platelet-rich plasma (PRP) injections can be financially burdensome, leading some individuals to forgo potentially beneficial treatments. This not only creates inequities in healthcare access but also slows the widespread adoption of Orthobiologics, as patients may opt for more affordable, conventional treatments, even if they may not offer the same regenerative benefits.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the market by disrupting supply chains, delaying elective procedures, and limiting patient access to treatments. Many orthopedic clinics and hospitals paused non-emergency services, leading to a reduction in the demand for regenerative therapies like stem cell treatments and PRP injections. Additionally, financial constraints and concerns over infection risks led patients to delay or forgo treatments. However, the pandemic also accelerated interest in minimally invasive and non-surgical options, which may drive future growth in the market.

The lumbar fusion segment is expected to be the largest during the forecast period

The lumbar fusion segment is expected to account for the largest market share during the forecast period such as bone grafts or stem cells, to promote the healing and fusion of vertebrae in the lower back. By integrating orthobiologic therapies, lumbar fusion aims to enhance healing, reduce complications, and improve patient outcomes. As minimally invasive techniques gain traction, the demand for regenerative treatments in spinal surgery is expected to increase, offering better recovery options for patients.

The dental clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the dental clinics segment is predicted to witness the highest growth rate. These biologic therapies help accelerate tissue regeneration, reduce inflammation, and improve the overall success of dental surgeries. As awareness of regenerative medicine grows, more dental professionals are integrating Orthobiologics into their practice, providing patients with advanced, minimally invasive options for faster recovery and better long-term results, boosting the demand within the dental sector.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to increasing healthcare awareness. Countries like Japan, China, and India are seeing greater adoption of treatments such as stem cell therapy, platelet-rich plasma (PRP), and bone grafts. Growing healthcare infrastructure, along with a shift towards minimally invasive procedures, is driving demand for Orthobiologics. The market is also supported by improving regulatory frameworks and increasing investments in medical research and technology.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR. Technological advancements in regenerative medicine, including stem cell therapies, gene therapies, and platelet-rich plasma (PRP) treatments, have boosted the efficacy of orthobiologic treatments. These innovations have led to greater adoption among both patients and healthcare providers.Moreover, As more patients and healthcare professionals learn about the benefits of orthobiologic therapies, such as accelerated healing and reduced dependency on traditional drugs or surgeries, demand for these treatments has risen.

Key players in the market

Some of the key players in Orthobiologics Market include Bioventus LLC, Nuvasive, Inc., Anika Therapeutics, Inc., Alphatec Spine, Inc., Medtronic plc, Stryker Corporation, Globus Medical, Inc., Xtant Medical Holdings, Inc., Sanofi S.A., Orthofix Medical Inc., Bone Therapeutics SA, RTI Surgical, Inc. , Kuros Biosciences Ltd. , Smith & Nephew plc, Integra LifeSciences Holdings Corporation , Seaspine Holdings Corporation and Arthrex, Inc.

Key Developments:

In March 2025, Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies. DR-0201 is a potential first-in-class CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted phagocytosis..

In March 2024, Stryker announced a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC, a family-owned investment firm specializing in the neuro-musculoskeletal space, to create a newly formed company called VB Spine, LLC.

Product Types Covered:

  • Bone Grafts
  • Growth Factors
  • Platelet-Rich Plasma (PRP)
  • Stem Cells
  • Cell-Based Therapies
  • Other Product Types

Distribution Channels Covered:

  • Direct Sales
  • Indirect Sales
  • E-Commerce Platforms

Applications Covered:

  • Cervical Fusion
  • Lumbar Fusion
  • Thoracic Fusion
  • Hip Replacement
  • Shoulder Reconstruction
  • Dental Implants
  • Wound Healing
  • Microfracture Surgery
  • Ligament Repair
  • Other Applications

End Users Covered:

  • Hospitals
  • Ambulatory Surgical Centers
  • Orthopedic Clinics
  • Dental Clinics
  • Rehabilitation Centers
  • Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Orthobiologics Market, By Product Type

  • 5.1 Introduction
  • 5.2 Bone Grafts
    • 5.2.1 Autografts
    • 5.2.2 Allografts
    • 5.2.3 Synthetic Bone Grafts
  • 5.3 Growth Factors
    • 5.3.1 Bone Morphogenetic Proteins (BMPs)
    • 5.3.2 Platelet-Derived Growth Factor (PDGF)
    • 5.3.3 Vascular Endothelial Growth Factor (VEGF)
    • 5.3.4 Transforming Growth Factor-beta (TGF-B)
    • 5.3.5 Insulin-like Growth Factor (IGF)
  • 5.4 Platelet-Rich Plasma (PRP)
  • 5.5 Stem Cells
    • 5.5.1 Mesenchymal Stem Cells (MSCs)
    • 5.5.2 Hematopoietic Stem Cells
    • 5.5.3 Induced Pluripotent Stem Cells (iPSCs)
  • 5.6 Cell-Based Therapies
    • 5.6.1 Autologous Cell Therapy
    • 5.6.2 Allogeneic Cell Therapy
  • 5.7 Other Product Types

6 Global Orthobiologics Market, By Distribution Channel

  • 6.1 Introduction
  • 6.2 Direct Sales
  • 6.3 Indirect Sales
  • 6.4 E-Commerce Platforms

7 Global Orthobiologics Market, By Application

  • 7.1 Introduction
  • 7.2 Cervical Fusion
  • 7.3 Lumbar Fusion
  • 7.4 Thoracic Fusion
  • 7.5 Hip Replacement
  • 7.6 Shoulder Reconstruction
  • 7.7 Dental Implants
  • 7.8 Wound Healing
  • 7.9 Microfracture Surgery
  • 7.10 Ligament Repair
  • 7.11 Other Applications

8 Global Orthobiologics Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Ambulatory Surgical Centers
  • 8.4 Orthopedic Clinics
  • 8.5 Dental Clinics
  • 8.6 Rehabilitation Centers
  • 8.7 Research Institutes
  • 8.8 Other End Users

9 Global Orthobiologics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Bioventus LLC
  • 11.2 Nuvasive, Inc.
  • 11.3 Anika Therapeutics, Inc.
  • 11.4 Alphatec Spine, Inc.
  • 11.5 Medtronic plc
  • 11.6 Stryker Corporation
  • 11.7 Globus Medical, Inc.
  • 11.8 Xtant Medical Holdings, Inc.
  • 11.9 Sanofi S.A.
  • 11.10 Orthofix Medical Inc.
  • 11.11 Bone Therapeutics SA
  • 11.11 RTI Surgical, Inc.
  • 11.13 Kuros Biosciences Ltd.
  • 11.14 Smith & Nephew plc
  • 11.15 Integra LifeSciences Holdings Corporation
  • 11.16 Seaspine Holdings Corporation
  • 11.17 Arthrex, Inc.

List of Tables

  • Table 1 Global Orthobiologics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Orthobiologics Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Orthobiologics Market Outlook, By Bone Grafts (2024-2032) ($MN)
  • Table 4 Global Orthobiologics Market Outlook, By Autografts (2024-2032) ($MN)
  • Table 5 Global Orthobiologics Market Outlook, By Allografts (2024-2032) ($MN)
  • Table 6 Global Orthobiologics Market Outlook, By Synthetic Bone Grafts (2024-2032) ($MN)
  • Table 7 Global Orthobiologics Market Outlook, By Growth Factors (2024-2032) ($MN)
  • Table 8 Global Orthobiologics Market Outlook, By Bone Morphogenetic Proteins (BMPs) (2024-2032) ($MN)
  • Table 9 Global Orthobiologics Market Outlook, By Platelet-Derived Growth Factor (PDGF) (2024-2032) ($MN)
  • Table 10 Global Orthobiologics Market Outlook, By Vascular Endothelial Growth Factor (VEGF) (2024-2032) ($MN)
  • Table 11 Global Orthobiologics Market Outlook, By Transforming Growth Factor-beta (TGF-B) (2024-2032) ($MN)
  • Table 12 Global Orthobiologics Market Outlook, By Insulin-like Growth Factor (IGF) (2024-2032) ($MN)
  • Table 13 Global Orthobiologics Market Outlook, By Platelet-Rich Plasma (PRP) (2024-2032) ($MN)
  • Table 14 Global Orthobiologics Market Outlook, By Stem Cells (2024-2032) ($MN)
  • Table 15 Global Orthobiologics Market Outlook, By Mesenchymal Stem Cells (MSCs) (2024-2032) ($MN)
  • Table 16 Global Orthobiologics Market Outlook, By Hematopoietic Stem Cells (2024-2032) ($MN)
  • Table 17 Global Orthobiologics Market Outlook, By Induced Pluripotent Stem Cells (iPSCs) (2024-2032) ($MN)
  • Table 18 Global Orthobiologics Market Outlook, By Cell-Based Therapies (2024-2032) ($MN)
  • Table 19 Global Orthobiologics Market Outlook, By Autologous Cell Therapy (2024-2032) ($MN)
  • Table 20 Global Orthobiologics Market Outlook, By Allogeneic Cell Therapy (2024-2032) ($MN)
  • Table 21 Global Orthobiologics Market Outlook, By Other Product Types (2024-2032) ($MN)
  • Table 22 Global Orthobiologics Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 23 Global Orthobiologics Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 24 Global Orthobiologics Market Outlook, By Indirect Sales (2024-2032) ($MN)
  • Table 25 Global Orthobiologics Market Outlook, By E-Commerce Platforms (2024-2032) ($MN)
  • Table 26 Global Orthobiologics Market Outlook, By Application (2024-2032) ($MN)
  • Table 27 Global Orthobiologics Market Outlook, By Cervical Fusion (2024-2032) ($MN)
  • Table 28 Global Orthobiologics Market Outlook, By Lumbar Fusion (2024-2032) ($MN)
  • Table 29 Global Orthobiologics Market Outlook, By Thoracic Fusion (2024-2032) ($MN)
  • Table 30 Global Orthobiologics Market Outlook, By Hip Replacement (2024-2032) ($MN)
  • Table 31 Global Orthobiologics Market Outlook, By Shoulder Reconstruction (2024-2032) ($MN)
  • Table 32 Global Orthobiologics Market Outlook, By Dental Implants (2024-2032) ($MN)
  • Table 33 Global Orthobiologics Market Outlook, By Wound Healing (2024-2032) ($MN)
  • Table 34 Global Orthobiologics Market Outlook, By Microfracture Surgery (2024-2032) ($MN)
  • Table 35 Global Orthobiologics Market Outlook, By Ligament Repair (2024-2032) ($MN)
  • Table 36 Global Orthobiologics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 37 Global Orthobiologics Market Outlook, By End User (2024-2032) ($MN)
  • Table 38 Global Orthobiologics Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 39 Global Orthobiologics Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 40 Global Orthobiologics Market Outlook, By Orthopedic Clinics (2024-2032) ($MN)
  • Table 41 Global Orthobiologics Market Outlook, By Dental Clinics (2024-2032) ($MN)
  • Table 42 Global Orthobiologics Market Outlook, By Rehabilitation Centers (2024-2032) ($MN)
  • Table 43 Global Orthobiologics Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 44 Global Orthobiologics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.